Linezolid for XDR-TB - Final study outcomes

New England Journal of Medicine

Volumn 373, Issue 3, 2015, Pages 290-291

  Lee, Myungsun ^a   Cho, Sang Nae ^b   Barry, Clifton E ^c  

^a International Tuberculosis Research Center   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PROTEIN SYNTHESIS INHIBITOR; TUBERCULOSTATIC AGENT;

ANEMIA; CLINICAL EFFECTIVENESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FOLLOW UP; HUMAN; LETTER; OPTIC NERVE DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TREATMENT OUTCOME;

ACETAMIDES; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; PROTEIN SYNTHESIS INHIBITORS; SPUTUM; TREATMENT OUTCOME;

EID: 84937027327     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1500286     Document Type: Letter

References (5)

1. Lee M, Lee J, Carroll M.W., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367:1508-18.
2. Hillemann D, Rüsch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2008; 52:800-1.
3. Tang S, Yao L, Hao X., et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J 2015; 45:161-70.
4. Nunn AJ, Phillips PP, Mitchison DA Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis 2010; 14:241-2.
5. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40:1430-42.